Clinical Trials
70 trialsSELECTmeso
University of Southampton
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center
A Study of Sacituzumab Govitecan in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
ANTARES
Instituto do Cancer do Estado de São Paulo
Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma
Fudan University
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
MesoPDT
University Hospital, Lille
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
BIMES
Fundación GECP
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
MAGIC-AKI
Brigham and Women's Hospital
KEYNOTE 158
Merck Sharp & Dohme LLC
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Memorial Sloan Kettering Cancer Center
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
Azienda USL Reggio Emilia - IRCCS
NERO
University Hospital Southampton NHS Foundation Trust
Olaparib in Patients With HRD Malignant Mesothelioma
University of Chicago
ACROPOLI
SOLTI Breast Cancer Research Group
RAMES
Gruppo Oncologico Italiano di Ricerca Clinica
Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
Ain Shams University
NIPU
Oslo University Hospital
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Verastem, Inc.
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
University of Chicago
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
Bayer
PrE0505
PrECOG, LLC.
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Eastern Cooperative Oncology Group
UNITO-001
University of Turin, Italy
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
M.D. Anderson Cancer Center
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Baylor College of Medicine
Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma
University of Calgary
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
VIM
Wales Cancer Trials Unit
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
Swiss Cancer Institute
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
Epizyme, Inc.
Olaparib in People With Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
MAPS2
Intergroupe Francophone de Cancerologie Thoracique
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Bayer
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
University of Texas Southwestern Medical Center
ATREUS
Mario Negri Institute for Pharmacological Research
Mithramycin for Lung, Esophagus, and Other Chest Cancers
National Institutes of Health Clinical Center (CC)
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
Columbia University
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Mayo Clinic
SIGNATURE
Novartis
HIPEC/IPHC
Bay Area Gynecology Oncology
18F-FSPG PET/CT for Cancer Patients on Therapy
Stanford University